PYRIDOTIENOTRIAZINES AS ANTIANGIOGENIC COMPOUNDS
Description
Angiogenesis is the generation of new capillaries from pre-existing vessels. Under physiological conditions, angiogenesis is under very strict control and only occurs during embryonic development and in processes related to the female reproductive cycle, fracture repair and wound healing. However, in many pathological processes (for example tumor growth and its dissemination in metastases, ophthalmic diseases such as diabetic retinopathy and macular degeneration, hemangiomas, arthritis, psoriasis, atherosclerosis ...), the disease has been related to a continuously deregulated angiogenesis active. Thus, dysregulation of angiogenesis may be the direct cause or exacerbate a certain pathological condition. In this sense, the present invention presents pyridothienotriazine derivatives with antioangiogenic activity and their use in the preparation of pharmaceutical compositions or drugs for the treatment of diseases is those that are involved in the angiogenesis process, such as cancer, obesity, retinopathies diabetics, macular degeneration, hemangiomas, arthritis, psoriasis and atherosclerosis.
Advantages
At present there is a continuing need to find compounds that show antiangiogenic activity, due to their potential use in the treatment of various pathologies, including cancer. The compounds object of the present invention respond to this need. The preparation of pharmaceutically acceptable salts, prodrugs and derivatives thereof can be carried out by conventional chemical methods. Administration of these compounds or their compositions can be by any suitable method, such as intravenous infusion, oral preparations, or intraperitoneal and intravenous administration. Oral administration is preferred due to convenience to the patient and the chronic nature of the diseases to be treated.
Uses and Applications
The present technology has its application in the preparation of drugs for the treatment of angiogenesis-dependent diseases (in particular cancer, ophthalmic diseases such as diabetic retinopathy and macular degeneration, hemangiomas, arthritis, psoriasis, atherosclerosis, etc.).
Keywords
Sectors
Areas
Patent Number
ES2343880
Applicants
Universidad De Málaga
Inventors
Ana Maria Rodriguez Quesada, Beatriz Martínez Poveda, Miguel Angel Medina Torres, Ramon Muñoz, Antonio Fernández Medarde, José María Quintela López, Ricardo Jesús Riguera Vega
Filing Date
10/05/2007
Protection Level: National (Spain)
Processing Status: Spanish patent
